Happy to share our article on Clonal Hematopoiesis in phase I patients. ⚠️Prevalence of 41% No impact on OS, slight PFS benefit with targeted therapies No major toxicity Capu B Gustave Roussy doi.org/10.1200/PO.23.…

Out in Nature Aging today, Tara Mack & Michael Raddatz identify epigenetic and proteomic signatures associated with #CHIP clonal expansion nature.com/articles/s4358…

CONGRESS | #ASCO24 Alexandre Bazinet MD Anderson Cancer Center demonstrated that, in unfit patients with ND AML, 7-day courses of HMA-Ven were associated with similar CRc rates, and potentially less myelosuppression and early mortality, vs standard dosing. Prognostic risk signature

What better way 2 begin the academic year than 2 learn the “16+2” molecular subgroups of #MDSsm …. Never a better time to be a #hematopathologist 🎉 Going frm 3 genetically defined groups (multi TP53, SF3B1 and del 5q) of MDS to 16 👇🏼is a major advancement in our understanding

How does clonal haematopoiesis evolve to leukaemia (AML)?🩸How long does it take?⏳ ⭐️Excited to share our preprint!⭐️ Using serial blood samples collected BEFORE diagnosis of AML we unveil the somatic evolution📈 that occurs in the decades pre-diagnosis: biorxiv.org/content/10.110…

🎓 Félicitations aux cinq lauréats des concours CNRS/Inserm Chaque année, le CNRS 🌍 et l’Inserm organisent des concours très sélectifs pour recruter leurs nouveaux chercheurs titulaires. Cette année, parmi les cinq lauréats pour Gustave Roussy, quatre mènent déjà des recherches

The Olympic flame today Gustave Roussy carried by a young cured patient, relayed by two staff members, symbolizing the flame that drives staff, doctors & researchers in the service of patients living with #cancer #1⃣ in Europe 🙏Val-de-Marne Ville de Villejuif JoParis2024

Happy to share our article on lenalidomide-associated Acute Lymphoblastic Leukemia. We hope that it may help the physicians to better monitor this risk. nature.com/articles/s4140…

Out in print! Risk prediction for clonal cytopenia: multicenter real-world evidence | Blood | American Society of Hematology | ⁦Proud to have contributed to this multicenter collaboration!@SylvesterCancer⁩ #CCUS #MDSsm #leusm #hematology ashpublications.org/blood/article/…

Sad as yet another randomized, Phase 3 Trial in higher-risk #MDSsm - this one of AZA + Tamibarotene vs AZA alone with RARA+ - fails. We need to power these adequately to show incremental overall survival improvement, and not focus on CR! ☹️🩸😡 ⁦ ir.syros.com/press-releases…

Out in @BloodJournal today, Alyssa Parker developed an accurate way to monitor clonal dynamics in #CHIP that makes short term changes in clone size a reliable readout for clinical trials. @VUMCgenetics Vanderbilt University Medical Center 👇

I’m very thrilled to presented our work at ASH 2024 Congress, 07/12/24, 5.30-7.30 pm. Clonal Hematopoiesis and Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors an association to watch ! A big thanks to the whole participated centers and to Jean-Baptiste Micol #ASH2024

Congrats to our PhD student, Pierre-Edouard Debureaux, MD, PhD Student and all co-authors for this collaborative work performed with Saint Louis, Cochin, Pitié Salpétrière, Lille, Necker, Mondor and Avicenne hospital on Inflammatory Waldenstrom and Clonal hematopoiesis paper published in Blood Journal!

Read this study by Dawi et al regarding tumor fraction liquid biopsy performed for tumor burden assessment and how well it correlated with total tumor volume at CT. bit.ly/3VaG93o

Huge work of Gustave Roussy Radiology Department and MTB: "Liquid Biopsy versus CT: Comparison of Tumor Burden Quantification in 1065 Patients with Metastases". 📌Article: doi.org/10.1148/radiol… 📌Editorial: doi.org/10.1148/radiol…

A nice commentary in this issue of Blood Journal for our paper looking at the role of #ClonalHematopoiesis in #TBD from Chris Reilly and Mikko Myllymäki - a somatic symphony; telomeres and CH! ashpublications.org/blood/article/… Fernanda Gutierrez-Rodrigues Sharon A. Savage, M.D. ashpublications.org/blood/article/…

Cancer survivors are growing in number. In the US, nearly half of survivors have lived 10 or more years after diagnosis, while 19% have lived 20 or more years. The prevalence of long-term survivors is expected to increase through 2040. go.nih.gov/rOUbZJD #CancerSurvivorship

Cette nouvelle étape reflète l'engagement de Gustave Roussy à toujours placer nos #patients au coeur de nos priorités et à renforcer notre mission de #soins et d'#innovation pour tous. Le progrès, c'est aussi rendre la santé plus accessible !

Delighted to share our work on clonal hematopoiesis #CH out now in Nature Genetics. We revealed ancestry as a risk factor for CH 🧵 AstraZenecaUK Cambridge University nature.com/articles/s4158…

📣 We are excited to announce the first scientific day on liquid biopsy, organized by Gustave Roussy and the Prism Center, taking place on June 11, 2025, in Paris! 🧬🔬 🔗 More information & registration: gustaveroussy.my.site.com/formation/s/fo…